Electrophysiological effects of short-term antihypertensive therapy

References

• Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am. J. Cardiol.60, 560–565 (1987).
   PubMed Web of Science ®Google Scholar
• McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N. Engl. J. Med.317, 787–792 (1987).
   PubMed Web of Science ®Google Scholar
• Schillaci G, Verdecchia P, Borgioni C et al. Association between persistent pressure overload and ventricular arrhythmias in essential hypertension. Hypertension28, 284–289 (1996).
   PubMed Web of Science ®Google Scholar
• Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol.32, 1454–1459 (1998).
   PubMed Web of Science ®Google Scholar
• Okin PM, Wachtell K, Devereux RB et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA296(10), 1242–1248 (2006).
   PubMed Web of Science ®Google Scholar
• Porthan K, Viitasalo M, Hiltunen TP et al. Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Ann. Med. DOI:10.1080/078538 90802195211 (2008) (Epub ahead of print).
   Google Scholar
• Ainscough JF, Drinkhill MJ, Sedo A et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc. Res. DOI:10.1093/cvr/cvn230 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail. Rev.13(3), 367–375 (2008).
   PubMed Web of Science ®Google Scholar
• Delpon E, Caballero R, Gomez R, Nunez L, Tamargo J. Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol. Sci.26, 155–161 (2005).
   PubMed Web of Science ®Google Scholar
• Viitasalo M, Oikarinen L, Swan H et al. Effects of β-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome. J. Am. Coll. Cardiol.48, 747–753 (2006).
   PubMedGoogle Scholar
• Siscovick DS, Raghunathan TE, Psaty BM et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N. Engl. J. Med.330, 1852–1857 (1994).
   PubMed Web of Science ®Google Scholar
• Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (the GENRES study). Am. J. Hypertens.20, 311–318 (2007).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol.57, 450–458 (1986).
   PubMed Web of Science ®Google Scholar
• Liu JE, Devereux RB. Clinical assessment of cardiac hypertrophy. In: Left Ventricular Hypertrophy. Sheridan DJ (Ed.). Churchill Livingstone, London, UK (1998).
   Google Scholar
• Karjalainen J, Viitasalo M, Mänttäri M, Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J. Am. Coll. Cardiol.23, 1547–1553 (1994).
   PubMed Web of Science ®Google Scholar
• Yiu KH, Tse HF. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications. J. Hum. Hypertens.22(6), 380–388 (2008).
   PubMedGoogle Scholar
• Messerli FH. Hypertension and sudden cardiac death. Am. J. Hypertens.12(3), 181S–188S (1999).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation116(7), 700–705 (2007).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S et al.; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA292(19), 2343–2349 (2004).
   PubMed Web of Science ®Google Scholar
• Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin–angiotensin system. Annu. Rev. Physiol.54, 227–241 (1992).
   PubMed Web of Science ®Google Scholar
• Caballero R, Delpón E, Valenzuela C, Longobardo M, Tamargo J. Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents. Circulation101(10), 1199–1205 (2000).
   PubMed Web of Science ®Google Scholar
• Zicha S, Tsuji Y, Shiroshita-Takeshita A, Nattel S. β-blockers as antiarrhythmic agents. Handb. Exp. Pharmacol.171, 235–266 (2006).
   Google Scholar
• Blumenfeld JD, Sealey JE, Mann SJ et al. β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin–angiotensin–aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens.12(5), 451–459 (1999).
   PubMed Web of Science ®Google Scholar
• Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J. Am. Coll. Cardiol.43(2), 155–161 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation100(12), 1311–1315 (1999).
   PubMed Web of Science ®Google Scholar
• ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA265(24), 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar